ONCOVID is a prospective cohort study investigating oncology-patient-reported anxiety, mood, and quality of life during the COVID-19 pandemic. Participants complete a survey consisting of sociodemographic information and self-administered questionnaires (COVID-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, and WHO Quality of Life-BREF). Data collection occurs at baseline and follow-up surveys are performed after 6, 12, and 24 weeks.
Other: Survey administration
Covid-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, WHO Quality of Life-BREF
Inclusion Criteria:
- ≥ 18 years of age
- Histologically confirmed cancer
- Receive systemic therapy (including chemotherapy, targeted small-molecule therapy,
anticancer monoclonal antibody, immunotherapy, endocrine therapy, or investigational
agent) (either exclusively or in combination with other anticancer therapy) between
February 14, 2020 and March 31, 2020 (Note: Patients whose systemic treatment
administration was initially planned for this period but was modified, delayed,
stopped, or withheld due to COVID-19 measures are also eligible for inclusion)
Exclusion Criteria:
- Insufficient understanding of the Dutch language
- Severe cognitive impairment
- Acute psychiatric crisis
- Not able to give informed consent
- Confirmed or clinically suspected COVID-19
- Endocrine therapy in (neo)adjuvant setting (Note: Patients whose (neo)adjuvant
systemic treatment was initially planned as chemotherapy, targeted small-molecule
therapy, anticancer monoclonal antibody, immunotherapy, or investigational agent
(either exclusively or in combination in combination with other anticancer therapy)
but was modified to endocrine therapy due to COVID-19 measures are also eligible for
inclusion)
University Hospital Gent
Gent, Belgium
Hannelore Denys, MD, PhD, Principal Investigator
Medical Oncologist